Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has provided an update.
CARsgen Therapeutics has launched a top-up placing and subscription of up to 23.7 million shares, representing about 4.15% of its existing issued share capital, at HK$19.84 per share, a discount to recent market prices. The structure involves an existing shareholder selling shares to placing agents with a matching subscription for new shares under a general mandate, alongside a 90-day lock-up to signal long-term support.
The company expects to deploy roughly 70% of net proceeds into global R&D for its innovative drug pipeline, including allogeneic and in vivo CAR T-cell products and related clinical trials. The remaining funds will be directed to R&D and manufacturing infrastructure and to working capital and commercialization efforts, bolstering CARsgen’s operational capacity and positioning in the competitive cell therapy space.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company focused on developing innovative CAR T-cell therapies for oncology indications. The group pursues global clinical development, including in China, and invests in research, manufacturing facilities and commercialization capabilities to advance its cell therapy pipeline across multiple product candidates and indications.
Average Trading Volume: 5,773,827
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.1B
For detailed information about 2171 stock, go to TipRanks’ Stock Analysis page.